Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flat-dose nivolumab plus ipilimumab safety study in non-small cell lung cancer
NL-OMON47686Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoint: High-grade treatment-related select and immune-mediated adverse events. Started Apr 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47686.